Clinical Trial Update: The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing IL13-PE38QQR against GLIADEL wafer in patients with recurrent glioblastoma multiforme has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• GLIADEL wafer (carmustine)
• IL13-PE38QQR

Snippet

Sponsor: INSYS Therapeutics Inc | Conditions: Glioblastoma Multiforme | Phase 3 | Status: COMPLETED